2019年10月30日 · PPSV23. PPSV23 protects against 23 types of bacteria that cause pneumococcal disease. PPSV23 is recommended for: All adults 65 years or older, Anyone 2 years or older with certain medical conditions that can lead to an increased risk for pneumococcal disease. Most people need only one dose of PPSV23.

2024年9月12日 · Studies show PPSV23 protects between 6 to 7 in 10 adults with healthy immune systems from invasive pneumococcal disease. This protection is against pneumococcal infections caused by serotypes in the vaccine.

2024年10月26日 · If PCV15 is used, administer a dose of PPSV23 A one year later, if needed B. Their pneumococcal vaccinations are complete. The minimum interval is 8 weeks and can be considered in adults with: An immunocompromising condition. A cochlear implant. A cerebrospinal fluid leak. PCV20 or PCV21: Additional vaccination not recommended

2025年1月1日 · A systematic review found that PPSV23 had a moderate or non-significant VE on vaccine-type pneumococcal pneumonia (18%, 95% CI: 4-35%) in adults, while PCV13 had an increasingly stronger effect with a range of 38–68% [52].

This review shows that PPSV23 is effective against vaccine-type invasive pneumococcal disease and vaccine-type pneumococcal pneumonia and can lower the burden of vaccine-type pneumococcal pneumonia. PPSV23-conferred protection may be lower in adults aged ≥75 years, those with certain underlying conditions, and individuals who were vaccinated ...

2024年6月7日 · 在医学术语中，"PPV23"是"Pneumococcal Polysaccharide Vaccine (23-valent) (replaced by the term PPSV23)"这一疫苗的简称，中文直译为“肺炎球菌多糖疫苗（23价）”。 这个疫苗主要用于预防由肺炎链球菌引起的疾病，尤其在老年人和高风险群体中广泛应用。

For persons ≥ 2 years of age, numerous studies have shown that PPV23 is effective in preventing IPD. Recent studies from Russia, 21 China 22 and Japan 23 demonstrated that geometric mean antibody titers (GMTs) to all tested serotypes increased dramatically after PPV23 vaccination.

本文件最后部分列举了WHO 关于PPV23的最新接种建议,并介绍了关于主要结论和政策陈述的科学证据的质量水平。 受篇幅所限,本文仅提供了有限的参考文献。 有关PPV23 的更多信息,包括更多的参考文献以及证据分级资料,参见. http://www.who.int/immunization/documents/positionpapers/en/index.html。 之前已经公布了婴幼儿使用的 价多糖蛋白结合疫苗)的立场文件。 肺炎链球菌(Sp )是全球儿童和成人致病和致死的 …

A prior systematic review indicated that both PCV13 and PPSV23 are effective in preventing vaccine-type invasive pneumococcal disease (VT-IPD) and vaccine-type pneumococcal pneumonia in adults . Another meta-analysis demonstrated that the PPSV23 vaccination provides a significant protective benefit against invasive pneumococcal diseases (IPDs).

23价肺炎球菌多糖疫苗是科兴首个细菌类疫苗产品，于2020年12月2日获批上市，以欧洲药典和WHO规程严格控制疫苗质量，为2岁以上人群，尤其是老年人、慢病人群等重点人群预防肺炎球菌侵袭性疾病提供安心呵护。 创新层析技术，高效去除致敏杂质，降低不良反应风险. 生产全过程零防腐剂添加有效成分清晰，接种更安心. 五条工艺路线，精准纯化方案，保护抗原完整. 【药品名称】通用名称：23价肺炎球菌多糖疫苗. 【成分和性状】本品系采用23种广泛流行、具侵袭性的 …